BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 28504720)

  • 1. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
    Choi EJ; Jung BJ; Lee SH; Yoo HS; Shin EA; Ko HJ; Chang S; Kim SY; Jeon SM
    Oncogene; 2017 Sep; 36(37):5285-5295. PubMed ID: 28504720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
    Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
    Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
    Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
    Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
    Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
    Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
    Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
    Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
    Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
    Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
    J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
    Zhang B; Ma Z; Tan B; Lin N
    Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
    Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydrotanshinone I inhibits gallbladder cancer growth by targeting the Keap1-Nrf2 signaling pathway and Nrf2 phosphorylation.
    Li Z; Mo RL; Gong JF; Han L; Wang WF; Huang DK; Xu JG; Sun YJ; Chen S; Han GC; Sun DQ
    Phytomedicine; 2024 Jul; 129():155661. PubMed ID: 38677269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.
    Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY
    Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
    Singh A; Venkannagari S; Oh KH; Zhang YQ; Rohde JM; Liu L; Nimmagadda S; Sudini K; Brimacombe KR; Gajghate S; Ma J; Wang A; Xu X; Shahane SA; Xia M; Woo J; Mensah GA; Wang Z; Ferrer M; Gabrielson E; Li Z; Rastinejad F; Shen M; Boxer MB; Biswal S
    ACS Chem Biol; 2016 Nov; 11(11):3214-3225. PubMed ID: 27552339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
    Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
    Lu MC; Shao HL; Liu T; You QD; Jiang ZY
    Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
    Lu MC; Ji JA; Jiang ZY; You QD
    Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2.
    Baird L; Suzuki T; Takahashi Y; Hishinuma E; Saigusa D; Yamamoto M
    Mol Cell Biol; 2020 Oct; 40(22):. PubMed ID: 32868290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.